Hyperbaric Oxygen Therapy Facilitates Stem Cell Implantation: Yet Another Beneficial Effect of HBOT by Paul G. Harch, MD
Hyperbaric Oxygen Therapy Facilitates Stem Cell Implantation: Yet Another Beneficial Effect of HBOT:
For 347 years HBOT has been thought to be a treatment for specific diseases. In fact, it is a treatment for the disease processes that underlie these diseases. Because these disease processes are shared by all diseases, HBOT is effective for a wide range of diseases/conditions. In addition to these disease processes, there are thousands of other targets in the human body that HBOT acts upon. In particular in the cells that line all of the smallest blood vessels in our body, endothelial cells, 8,101 genes of our 19,000 genes are responsive to changes in pressure and oxygen. Because of the vast array of HBOT-responsive targets HBOT is considered a foundation biological treatment. In the past 15 years research is suggesting another exciting effect of HBOT, it’s effect on stem cells. In this talk Dr. Harch will review the information that is showing that HBOT releases stem cells from the bone marrow into our circulation, stimulates stem cells at the site of injury in our body, including the brain, facilitates implantation of stem cells injected into the human body, and most recently, stimulates proliferation of stem cells in our fatty tissue that can then be harvested for use.
About Paul G. Harch, MD:
Paul G. Harch, M.D. is an emergency medicine and hyperbaric medicine clinician who is Clinical Professor of Medicine, Section of Emergency Medicine, at LSU School of Medicine, New Orleans, and former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Dr. Harch initiated and maintains a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system that spawned the subsequent academic and research practice. Beginning with brain injured divers and boxers in 1989, he applied his protocol to the first HBOT-treated cerebral palsy (1992) and autistic children (1996-2000) in this country and multiple other cerebral disorders, including most recently the first PET documented Alzheimer’s case (1/2019) and a subacute drowned child (Medical Gas Research 3/2017). This drowning case was the first demonstration of global regrowth of brain tissue in humans. He has now treated the largest series of drowned children in the world, over 100 children. In addition, He has successfully treated U.S. servicemen with TBI and PTSD, publishing the first case in 2009, a case series in 2012, a case-controlled series in 2019, and in March, 2020 a randomized controlled trial in civilians and veterans with mild traumatic brain injury. This human work was buttressed by application of the human protocol to animals in 2007 that stands as the
first and only improvement of chronic brain injury in animals in the history of science. Dr. Harch’s work and perspective on hyperbaric oxygen therapy was published in his book, The Oxygen Revolution, where HBOT is explained as an epigenetic therapy with expected revolutionary effects on medicine and neurology. In March, 2020 he proposed the application of HBOT to COVID-19 pneumonia based on the successful use of hyperbaric treatment for dying Spanish Flu patients in 1918 and has now successfully treated patients with COVID-19 Long-Haulers Syndrome.